See the latest Boehringer Ingelheim news releases. To quickly find all news releases on a specific topic, please use the fulltext search.
Head-to-head trial demonstrates Viramune®’s similar efficacy and more favourable effect on lipid profile compared to atazanavir/ritonavir
Successful promissory note (Schuldschein) placement
European Commission approves statement on lipid improvement for Viramune® label
Boehringer Ingelheim receives positive recommendation from European scientific committee for a new once daily Mirapexin (pramipexole) formulation for the treatment of Parkinson`s disease
Expedition to Mount Everest offers new insights into chronic disease
Boehringer Ingelheim and Vitae Pharmaceuticals announce a major collaboration to research and develop novel treatments for Alzheimer`s disease
New investigational combination telmisartan and amlodipine shows effective and well-tolerated 24-hour blood pressure control in hypertensive patients at risk of cardiovascular events
New data once more show high therapeutic benefits of Boehringer Ingelheim`s Mirapexin®/Sifrol® (pramipexole) once-daily extended release formulation, also in patients with advanced Parkinson`s disease
New data from Boehringer Ingelheim`s ongoing linagliptin trial programme show promising safety and efficacy results
Boehringer Ingelheim and DxS sign an agreement for a companion diagnostic to identify EGFR mutations in patients with lung cancer
Boehringer Ingelheim and the World Stroke Organization announce partnership in the World Stroke Academy
Boehringer Ingelheim to present new phase II clinical data on two lead oncology compounds at ASCO 2009
Boehringer Ingelheim and DeveloGen AG announce agreement in the field of diabetes, obesity and the metabolic syndrome
Exelixis and Boehringer Ingelheim enter into collaboration for development of S1P1 receptor agonists in the field of autoimmune diseases
Outcome of new Mirapexin®/ Sifrol® (pramipexole) study set to change treatment of depressive symptoms in Parkinson`s disease
New study results support once daily, prolonged release formulation of Mirapexin®/ Sifrol®(pramipexole) for the treatment of Parkinson`s disease
No increased risk of treatment-induced augmentation in Restless Legs Syndrome (RLS) demonstrated in long-term placebo-controlled study with Mirapexin®/ Sifrol® (pramipexole)
Boehringer Ingelheim maintains its growth path in 2008, again growing faster than the pharmaceutical market - major investments once again in Research and Development - good outlook for further growth in 2009